Skip to main
RNAC

RNAC Stock Forecast & Price Target

RNAC Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cartesian Therapeutics is well-positioned in the emerging in vivo CAR-T landscape, with plans to advance multiple internally-developed anti-BCMA CAR constructs and CAR-T cell engagers through their partnership with WestGene, positioning the company advantageously in the sector. The company's Phase 2 and 3 trials for Descartes-08 in MG and myositis are on track for data readouts in 1H27, and its differentiated profile compared to DNA-based CAR-T therapies make it a promising option for treating autoimmune diseases. Additionally, Cartesian's in-house mRNA manufacturing capabilities provide a competitive advantage in terms of cost structure, further supporting the commercial case for Descartes-08. However, as with any drug development company, Cartesian faces standard risks and uncertainties associated with clinical trials and regulatory approval that may affect its success in the market.

Bears say

Cartesian Therapeutics is a clinical-stage biopharmaceutical company pioneering a cell therapy approach using mRNA to treat autoimmune diseases. While the Phase 3 data for Descartes-08 in treatment-resistant myasthenia gravis is expected in 2027, there are concerns about the potential for safety issues and limited durability of current MG treatments. Additionally, current approved Txs for MG are suppressive rather than curative, creating a need for new therapies with less frequent dosing and potential for functional cures.

RNAC has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cartesian Therapeutics Inc (RNAC) Forecast

Analysts have given RNAC a Strong Buy based on their latest research and market trends.

According to 5 analysts, RNAC has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cartesian Therapeutics Inc (RNAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.